Necrostatin-1 and necroptosis inhibition: Pathophysiology and therapeutic implications

Autor: Liyuan Cao, Wei Mu
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
SIRS
systemic inflammatory response syndrome

PRR
pattern recognition receptor

ALI
acute lung injury

Indoles
Anti-Inflammatory Agents
Future application
Disease
RIP3
receptor interacting protein 3

ICH
intracerebral hemorrhage

Bioinformatics
HIV-1
human immunodeficiency virus type 1

LDL
low density lipoprotein

PYGL
glycogen phosphorylase

0302 clinical medicine
TRAF2
TNFR-associated factor 2

MLKL
mixed lineage kinase domain-like protein

HG
high glucose

GSH
glutathione

Medicine
FADD
fas associated via death domain

HI
hypoxia-ischemia

PCD
programmed cell death

AMD
age-related macular degeneration

Nec-1s
Necrostatin-1 stable

Lung
NF-κB
nuclear factor kappa B

Research evidence
COVID-19
coronavirus disease 2019

RIP1
receptor interacting protein 1

TNF
tumor necrosis factor

ERS
endoplasmic reticulum stress

mTOR
mechanistic target of rapamycin

Imidazoles
ALS
amyotrophic lateral sclerosis

RGAG
advanced glycation end products

Pathophysiology
RDA
RIP1-dependent apoptosis

IDO
indoleamine 2
3-dioxygenase

Necrostatin-1
030220 oncology & carcinogenesis
Nec-1i
Necrostatin-1 inactive

Necroptosis
Host-Pathogen Interactions
MI
myocardial infarction

LPS
lipopolysaccharide

MTH-Trp
methyl-thiohydantoin-tryptophan

TNFR1
TNF receptor 1

Signal Transduction
Programmed cell death
Coronavirus disease 2019 (COVID-19)
PARP1
polymerase 1

I/R
Ischemia-reperfusion

AKI
acute kidney injury

Disease models
AD
Alzheimer’s disease

Article
TBI
traumatic brain injury

MPTP
mitochondrial permeability transition pore

03 medical and health sciences
SCI
spinal cord injury

ROS
reactive oxygen species

ox-LDL
oxidized LDL

Animals
Humans
CaMKII
Ca2+/calmodulin-dependent protein kinase II

ComputingMethodologies_COMPUTERGRAPHICS
PD
Parkinson’s disease

Pharmacology
AAA
abdominal aortic aneurysm

business.industry
SARS-CoV-2
Nec-1
Necrostatin-1

COVID-19
LMP
lysosomal membrane permeabilization

SAH
subarachnoid Hemorrhage

digestive system diseases
cIAP1/2
cellular inhibitor of apoptosis proteins 1 and 2

RGCs
retinal ganglion cells

HD
Huntington’s disease

HMGB1
high mobility group box 1

IL
interleukin

RPE
retinal pigment epithelial

TRADD
TNFR-associated death domain

COVID-19 Drug Treatment
FHF
fulminant hepatic failure

RIA
RIP1-indipendent apoptosis

Disease Models
Animal

030104 developmental biology
DAMPs
damage-associated molecular patterns

necrostatin-1
business
Anti-Inflammation
Cyp-D
cyclophilin-D
Zdroj: Pharmacological Research
ISSN: 1043-6618
DOI: 10.1016/j.phrs.2020.105297
Popis: Graphical abstract
Necrostatin-1 (Nec-1) is a RIP1-targeted inhibitor of necroptosis, a form of programmed cell death discovered and investigated in recent years. There are already many studies demonstrating the essential role of necroptosis in various diseases, including inflammatory diseases, cardiovascular diseases and neurological diseases. However, the potential of Nec-1 in diseases has not received much attention. Nec-1 is able to inhibit necroptosis signaling pathway and thus ameliorate necroptotic cell death in disease development. Recent research findings indicate that Nec-1 could be applied in several types of diseases to alleviate disease development or improve prognosis. Moreover, we predict that Nec-1 has the potential to protect against the complications of coronavirus disease 2019 (COVID-19). This review summarized the effect of Nec-1 in disease models and the underlying molecular mechanism, providing research evidence for its future application.
Databáze: OpenAIRE